HC Wainwright & Co. maintains Arvinas at Buy, lowers price target to $13 from $18

What happened

HC Wainwright & Co. kept its Buy rating on Arvinas but lowered its price target to $13 from $18, a 27.8% decrease. The new target implies 72.9% upside from the November 2 close of $7.52.

Confirmed

Global impact / market context

A lower price target still marked Buy signals the analyst expects gains but less than before, so future profit expectations were trimmed. Investors holding Arvinas shares get a weaker upside estimate, which can reduce willingness to pay today's price.

Analyst inference

Arvinas closed at $7.52, far below the $13 target, showing the stock trades at a deep discount to analyst expectations. That gap can reflect doubt about the company's prospects or broad caution toward unprofitable drug developers.

Analyst inference

What to watch

1. Watch whether other analysts also cut their Arvinas price targets, since HC Wainwright's move to $13 from $18 may signal a wider reassessment of expected returns. Confirmed
2. Track Arvinas announcements on drug trials and partnerships, because concrete progress could support the Buy rating and narrow the gap to the $13 target. Proposed
3. Observe trading around $7.52, the November 2 close; holding above it suggests investors accept the reduced upside, while a break lower hints at fading confidence. Analyst inference

Evidence

• Original source link unavailable